Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers.

Cancer Sci · 2018 · PMC5765306 · PMID 29047188

Europe PMC DOI

hedged sentence

0.0940

closest p · 1.9× alpha

0.0940

boldest claim

The sentences

borderline significanceP = .094so close (0.05 < p ≤ 0.1)

Among patients treated with anthracycline‐based chemotherapy (n = 531), BRCA1 mRNA low expression patients had a significantly higher pCR rate than intermediate or high BRCA1 mRNA expression groups (24.6% vs 16.8% or 14.0%, P = .031) and retained borderline significance (OR = 1.54, 95% CI = 0.93‐2.56, P = .094) in multivariate analysis.

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.